Biotime acquired Geron's hESC portfolio and now AST owns them. Biotime has within it's ownership contracts with all it's subsidiaries the ability to sublicense the ip so that they can share Biotimes core ip as well as cross-license with one another.
In 2015 Biotime expanded their hESC patents with non-destructive embryonic progenitors for the use in clinical therapeutics such as the heart muscle, cartilage(13 different types), liver, etc.
Biotime in 2017 will release multiple products on the market. Renevia(next-gen cosmetic surgery), and breast, lung and bladder cancer diagnostic products(OnciCyte)
In late 2017 BTX's subsidiary OrthoCyte(cartilage regen) and ReCyte(heart and blood regen) will go public as they will announce partnerships for their cartilage and heart clinical trials.
Biotime owns 58% of OncoCyte, 54% of Asterias, 62% of CellCure.